Simbryo discloses $5.25M round for organoid-based fertility diagnostics
Yael Katz's biotech sold the offering to 24 investors as it began marketing an assay designed to predict embryo implantation outcomes.
By Ryan Merket · Published
Primary source: SEC
Why it matters
Simbryo is financing a commercial push for a functional uterine assay while its evidence remains at the preprint stage. Adoption will depend on whether clinics see predictive value beyond existing biopsy add-ons.
Yael Katz, founder and CEO of Simbryo Technologies, has raised $5.25 million for a fertility diagnostic that grows models of a patient's uterine lining and tests how they interact with stem-cell-derived embryo models.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.